VNDA · Vanda Pharmaceuticals Inc. · Documents
Market Cap
$307.76M
Shares
60.46M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 10-Q | 2026-08-06 | 2026-06-30 | |
| 8-K | 2026-08-05 | — | |
| 8-K | 2026-06-05 | 2026-06-04 | |
| Investor Event Transcript | 2026-05-19 | 2026-06-30 | |
| 10-Q | 2026-05-07 | 2026-03-31 | |
| 8-K | 2026-05-06 | — | |
| DEF 14A | 2026-04-23 | 2026-06-04 | |
| 8-K | 2026-04-22 | — | |
| 8-K | 2026-04-02 | 2026-03-29 | |
| 8-K | 2026-03-10 | — | |
| 8-K | 2026-02-23 | 2026-02-20 | |
| 8-K | 2026-02-19 | 2026-02-18 | |
| 10-K | 2026-02-12 | 2025-12-31 | |
| 8-K | 2026-02-11 | — | |
| 8-K | 2026-01-08 | 2026-01-07 | |
| 8-K | 2025-12-31 | 2025-12-30 | |
| 8-K | 2025-12-04 | — | |
| 8-K | 2025-11-28 | — | |
| 10-Q | 2025-10-30 | 2025-09-30 | |
| 8-K | 2025-10-29 | — | |
| 8-K | 2025-10-01 | — | |
| 10-Q | 2025-07-31 | 2025-06-30 | |
| 8-K | 2025-07-31 | — | |
| 8-K | 2025-06-05 | — | |
| 10-Q | 2025-05-08 | 2025-03-31 | |
| 8-K | 2025-05-07 | — | |
| DEF 14A | 2025-04-25 | 2025-06-05 | |
| 8-K | 2025-03-17 | 2025-03-14 | |
| 8-K | 2025-02-20 | 2025-02-18 | |
| 10-K | 2025-02-14 | 2024-12-31 | |
| 8-K | 2025-02-13 | — | |
| 8-K | 2025-01-27 | 2025-01-25 | |
| 10-Q | 2024-11-07 | 2024-09-30 | |
| 8-K | 2024-11-06 | — | |
| 8-K | 2024-10-15 | 2024-10-14 | |
| 8-K | 2024-10-03 | 2024-10-02 | |
| 8-K | 2024-09-19 | — | |
| 8-K | 2024-08-08 | 2024-08-07 | |
| 10-Q | 2024-08-01 | 2024-06-30 | |
| 8-K | 2024-07-31 | — | |
| 8-K | 2024-06-20 | 2024-06-19 | |
| 8-K | 2024-06-13 | — | |
| 8-K | 2024-06-06 | — | |
| 8-K/A | 2024-05-24 | 2024-05-17 | |
| 8-K | 2024-05-24 | — | |
| 8-K | 2024-05-20 | 2024-05-17 | |
| 10-Q | 2024-05-09 | 2024-03-31 | |
| 8-K | 2024-05-08 | — | |
| 8-K | 2024-05-07 | — | |
| 8-K | 2024-05-03 | — |
Showing 1–50 of 127 filings
Key facts
CIK
1347178
CUSIP
921659108
13F (30d)
53 filings
53 filers
Visit website
Investor relations